Vol. 6 No. 6 (2026): June
Reimbursement Reviews

Trastuzumab Deruxtecan (Enhertu)

decorative image of the issue cover

Published June 17, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Trastuzumab deruxtecan (Enhertu), powder for concentrate for solution for IV infusion (100 mg vial).
  • Indication: For the treatment of adult patients with unresectable, locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.